Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243308 | 1.00 | MAOA (0.43) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10151438 | 0.80 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL20751435 | 0.80 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5878430 | 0.77 | HTR2B (0.46) | MAOAMAOBCALML3HTR2B | |
| SCHEMBL9488919 | 0.77 | HTR2B (0.46) | MAOAMAOBCALML3HTR2B | |
| SCHEMBL9489070 | 0.77 | HTR2B (0.46) | MAOAMAOBCALML3HTR2B | |
| SCHEMBL12294536 | 0.77 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14168335 | 0.77 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10504741 | 0.76 | CA2 (0.42) | MAOAHTR2B | |
| SCHEMBL9489050 | 0.76 | CA2 (0.42) | MAOAHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392168-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2020-12-17 | — | — | US | disclosed |
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMB CHEMIE (DE) | 2019-04-18 | — | — | US | disclosed |
| US-9993469-B2 | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9993469-B2 | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20160130288-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130288-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160113921-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2016-04-28 | — | — | US | disclosed |
| US-20160113921-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2016-04-28 | — | — | US | disclosed |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-8268812-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fül Kombinatorische Chemie (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8158797-B2 | Oxazolidinone-quinolone hybrid antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158797-B2 | Oxazolidinone-quinolone hybrid antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392168-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES | NQO2, QARS1, RECQL | MAOA 2580/4885MAOB 1528/4885LMNA 3394/4885 |
| US-20160130288-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES | NQO2, OXA1L, QARS1 | MAOA 2656/4885MAOB 1564/4885LMNA 3425/4885 |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | MAOA 1013/4885MAOB 1111/4885LMNA 2580/4885 |
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | OXA1L, NQO2, NQO1 | MAOA 2294/4885MAOB 1677/4885LMNA 4306/4885 |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | MAOA 1595/4885MAOB 1428/4885LMNA 3615/4885 |
| US-20160113921-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | OXA1L, NQO2, NQO1 | MAOA 2294/4885MAOB 1677/4885LMNA 4306/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | MAOA 1013/4885MAOB 1111/4885LMNA 2580/4885 |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | MAOA 1595/4885MAOB 1428/4885LMNA 3615/4885 |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | OXA1L, TOP1, TOP2A | MAOA 1595/4885MAOB 1428/4885LMNA 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.